文献速递肾小球疾病

C3肾小球病患者对依库珠单抗的临床应答模式

Patterns of Clinical Response to Eculizumab in Patients With C3 Glomerulopathy.
PubMed 文献 · Am J Kidney Dis · 2018-02-09

该病例系列纳入26例C3肾小球病患者,接受依库珠单抗治疗中位14个月后,23%获整体临床应答,23%获部分应答,54%无应答。整体应答者基线eGFR更低、病程进展更快且肾活检示更多新月体形成,提示依库珠单抗可能对快速进展性新月体型C3肾小球病有效。

要点

  • 依库珠单抗治疗后23%患者获整体临床应答,23%部分应答,54%无应答。
  • 整体应答者基线eGFR更低、进展更快且肾活检新月体更多。
  • 非快速进展型C3肾小球病使用依库珠单抗获益似乎有限。

核心结论

  • 依库珠单抗可能是新月体性快速进展型C3肾小球病的潜在治疗选择。
  • 对非快速进展型C3肾小球病患者,依库珠单抗的获益似乎有限。

研究设计与样本

  • 病例系列研究,通过法国C3肾小球病注册数据库及加拿大魁北克一家儿科转诊中心识别2010至2016年接受依库珠单抗治疗的儿童和成人C3肾小球病患者。
  • 共纳入26例患者,其中13例为儿童/青少年。

主要发现

  • 26例患者中,22例(85%)在依库珠单抗前已接受激素、血浆置换或免疫抑制治疗,其中3例尽管治疗仍快速进展。
  • 依库珠单抗启动时,11例(42%)有慢性肾脏病,7例(27%)为快速进展性疾病,3例(12%)需透析。
  • 依库珠单抗治疗中位14个月后,6例(23%)获整体临床应答,6例(23%)获部分临床应答,14例(54%)无应答。
  • 与部分应答或无应答者相比,整体临床应答者基线eGFR更低、病程进展更快且肾活检示更多新月体形成。
  • 年龄、肾纤维化程度、肾病综合征频率、低血清C3和C3肾炎因子及可溶性C5b-9升高或补体基因变异在应答者与非应答者间无差异。

临床怎么用

  • 对于新月体性快速进展型C3肾小球病,可考虑使用依库珠单抗。
  • 对于非快速进展型C3肾小球病,依库珠单抗的获益可能有限。

局限性

  • 回顾性设计,无对照组。
  • 病例数相对较少。
  • 纳入儿童和成人病例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cases reports and small series of patients with C3 glomerulopathy have reported variable efficacy of eculizumab. STUDY DESIGN: Case series of C3 glomerulopathy. SETTING & PARTICIPANTS: Pediatric and adult patients with C3 glomerulopathy treated with eculizumab between 2010 and 2016 were identified through the C3 glomerulopathy French registry database, and a questionnaire was sent to participating French pediatric and adult nephrology centers, as well as one pediatric referral center in Québec, Canada. OUTCOMES: Global or partial clinical renal response. MEASUREMENTS: Evolution of serum creatinine and proteinuria values. RESULTS: 26 patients (13 children/adolescents) were included. 22 (85%) patients had received steroids, plasma exchange, or immunosuppressive therapy before eculizumab, and 3 of them had rapid progression of their kidney disease despite treatment. At the initiation of eculizumab therapy, 11 (42%) patients had chronic kidney disease, 7 (27%) had rapidly progressive disease, and 3 (12%) required dialysis. After eculizumab treatment (median duration, 14 months), 6 (23%) patients had a global clinical response; 6 (23%), a partial clinical response; and 14 (54%), no response. Compared with those who had a partial clinical or no response, patients who had a global clinical response had lower estimated glomerular filtration rates, a more rapidly progressive course, and more extracapillary proliferation on kidney biopsy. Age, extent of renal fibrosis, frequency of nephrotic syndrome, low serum C3 and C3 nephritic factor and elevated soluble C5b-9 concentrations, or complement gene variants did not differ between responders and nonresponders. LIMITATIONS: Retrospective design without a control group, relatively small number of cases, inclusion of pediatric and adult cases. CONCLUSIONS: Eculizumab appears to be a potential treatment for patients with crescentic rapidly progressive C3 glomerulopathy. Its benefit in patients with non-rapidly progressing forms seems to be limited.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Le Quintrec M, Lapeyraque AL, Lionet A, et al. Patterns of Clinical Response to Eculizumab in Patients With C3 Glomerulopathy. Am J Kidney Dis. 2018. PMID: 29429752. doi:10.1053/j.ajkd.2017.11.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。